Bone Biologics Cash Flow From Operations vs. Total Asset

BBLGW Stock  USD 27.80  0.00  0.00%   
Based on Bone Biologics' profitability indicators, Bone Biologics Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Bone Biologics' ability to earn profits and add value for shareholders. At this time, Bone Biologics' Debt To Assets are fairly stable compared to the past year. Price Book Value Ratio is likely to climb to 0.43 in 2024, whereas Operating Cash Flow Per Share is likely to drop (38.13) in 2024.
For Bone Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bone Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bone Biologics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bone Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bone Biologics Corp over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.14)
Return On Assets
(0.57)
Return On Equity
(1.19)
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bone Biologics Corp Total Asset vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth.
Bone Biologics Corp is rated fourth in cash flow from operations category among its peers. It is rated fifth in total asset category among its peers . At this time, Bone Biologics' Total Assets are fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Bone Total Asset vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Bone Biologics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(9.56 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Bone Biologics

Total Asset

 = 

Tangible Assets

+

Intangible Assets

 = 
3.74 M
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Bone Total Asset Comparison

Bone Biologics is currently under evaluation in total asset category among its peers.

Bone Biologics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bone Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bone Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Bone Biologics' change in net profit over the period of time. It can combine multiple indicators of Bone Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income(410.55)(431.08)
Operating Income-9.4 M-9 M
Income Before Tax-8.9 M-8.5 M
Net Loss-8.9 M-8.5 M
Total Other Income Expense Net479.6 K503.6 K
Income Tax Expense-2 M-1.9 M
Net Interest Income-730.2 K-766.7 K
Net Loss-6.5 M-6.8 M
Interest Income1.9 KK
Net Loss(34.01)(35.71)
Income Quality 1.07  0.70 
Net Loss(0.54)(0.51)

Bone Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bone Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bone Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bone Biologics' important profitability drivers and their relationship over time.

Use Bone Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bone Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bone Biologics will appreciate offsetting losses from the drop in the long position's value.

Bone Biologics Pair Trading

Bone Biologics Corp Pair Trading Analysis

The ability to find closely correlated positions to Bone Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bone Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bone Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bone Biologics Corp to buy it.
The correlation of Bone Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bone Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bone Biologics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bone Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bone Biologics position

In addition to having Bone Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run High Dividend Yield ETFs Thematic Idea Now

High Dividend Yield ETFs
High Dividend Yield ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.